Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
After golf on WRAL: Man dead, woman injured after a shooting in Durham. Why residents say it's part of a larger spike in crime this year
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Denali Therapeutics Inc
(NQ:
DNLI
)
24.77
+0.88 (+3.68%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
714,801
Open
24.11
Bid (Size)
20.00 (1)
Ask (Size)
26.00 (1)
Prev. Close
23.89
Today's Range
23.85 - 25.01
52wk Range
14.56 - 25.34
Shares Outstanding
121,640,069
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following
August 14, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q2 2024
August 01, 2024
DNLI stock results show that Denali Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
+15.80%
+15.80%
1 Month
+2.82%
+2.82%
3 Month
+31.06%
+31.06%
6 Month
+46.65%
+46.65%
1 Year
+7.60%
+7.60%
More News
Read More
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
August 01, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
4 Analysts Assess Denali Therapeutics: What You Need To Know
February 28, 2024
Via
Benzinga
Denali Therapeutics: Q4 Earnings Insights
February 27, 2024
Via
Benzinga
Denali Therapeutics Stock Gets Technical Rating Upgrade
July 16, 2024
Via
Investor's Business Daily
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
July 08, 2024
Via
InvestorPlace
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
June 03, 2024
Via
Benzinga
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
June 03, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
May 08, 2024
Via
Benzinga
DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024
May 07, 2024
Via
InvestorPlace
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 07, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
May 01, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
To the Moon and Beyond: 7 Stocks With Cosmic Potential
March 14, 2024
Via
InvestorPlace
Goldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To Know
February 29, 2024
Via
Benzinga
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
February 27, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 27, 2024
Via
Benzinga
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
February 27, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces $500 million Private Placement Equity Financing
February 27, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
February 12, 2024
Via
Benzinga
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
February 08, 2024
Via
InvestorPlace
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
February 07, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
February 01, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 08, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
January 02, 2024
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.